Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Non Operating Investment Income: 2023-2025

Historic Non Operating Investment Income for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to $196,000.

  • Mereo BioPharma Group's Non Operating Investment Income rose 432.20% to $196,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $668,000, marking a year-over-year increase of 186.64%. This contributed to the annual value of -$419,000 for FY2024, which is 271.02% down from last year.
  • Latest data reveals that Mereo BioPharma Group reported Non Operating Investment Income of $196,000 as of Q3 2025, which was up 294.06% from -$101,000 recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Non Operating Investment Income high stood at $542,000 for Q1 2023, and its period low was -$448,000 during Q1 2024.
  • Its 3-year average for Non Operating Investment Income is $33,700, with a median of -$64,000 in 2024.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first crashed by 182.66% in 2024, then skyrocketed by 432.20% in 2025.
  • Over the past 3 years, Mereo BioPharma Group's Non Operating Investment Income (Quarterly) stood at -$195,000 in 2023, then skyrocketed by 180.51% to $157,000 in 2024, then spiked by 432.20% to $196,000 in 2025.
  • Its Non Operating Investment Income stands at $196,000 for Q3 2025, versus -$101,000 for Q2 2025 and $416,000 for Q1 2025.